Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice

Antiviral Research

Volumn 91, Issue 3, 2011, Pages 314-320

  Chen, Lili ^a   Dou, Jie ^a   Su, Zhenzhen ^a   Zhou, Huimin ^a   Wang, Hui ^a   Zhou, Weidong ^a   Guo, Qinglong ^a   Zhou, Changlin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antiviral activity; Baicalein; Ribavirin; Synergistic activity

Indexed keywords

BAICALEIN; MATRIX PROTEIN; PLACEBO; RIBAVIRIN; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIOPHAGE; CELL CULTURE; CELL DIFFERENTIATION; CHINESE MEDICINE; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCUTELLARIA BAICALENSIS; SURVIVAL RATE; TRADITIONAL MEDICINE; VIRUS INFECTION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; CELL CULTURE TECHNIQUES; CELL LINE; DOGS; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; FLAVANONES; INFLUENZA A VIRUS, H1N1 SUBTYPE; KIDNEY; LUNG; MICE; MICE, INBRED ICR; ORTHOMYXOVIRIDAE INFECTIONS; RIBAVIRIN; SURVIVAL RATE; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; SCUTELLARIA BAICALENSIS;

EID: 79960985400     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.008     Document Type: Article

References (46)

1. Ahn H.C., Lee S.Y., Kim J.W., Son W.S., Shin C.G., Lee B.J. Binding aspects of baicalein to HIV-1 integrase. Mol. Cells 2001, 12:127-130.
2. Bai G.R., Chittaganpitch M., Kanai Y., Li Y.G., Auwanit W., Ikuta K., Sawanpanyalert P. Amantadine- and oseltamivir-resistant variants of influenza A viruses in Thailand. Biochem. Biophys. Res. Commun. 2009, 390:897-901.
3. Baranovich T., Saito R., Suzuki Y., Zaraket H., Dapat C., Caperig-Dapat I., Oguma T., Shabana I.I., Saito T., Suzuki H. Emergence of H274Y oseltamivir-resistant A (H1N1) influenza viruses in Japan during the 2008-2009 season. J. Clin. Virol. 2010, 47:23-28.
4. Browne M.J. Mechanism and specificity of action of ribavirin. Antimicrob. Agents Chemother. 1978, 15:748-753.
5. Chang P.C., Li H.Y., Tang H.J., Liu J.W., Wang J.J., Chuang Y.C. In vitro synergy of baicalein and gentamicin against vancomycin-resistant Enterococcus. J. Microbiol. Immunol. Infect. 2007, 2007:56-61.
6. Choi W.Y., Kim S., Lee N., Kwon M., Yang I., Kim M.J., Cheong S.G., Kwon D., Lee J.Y., Oh H.B., Kang C. Amantadine-resistant influenza A viruses isolated in South Korea from 2003 to 2009. Antiviral Res. 2009, 84:199-202.
7. Conner C.S. Ribavirin. Drug Intell Clin. Pharm. 1984, 18:137-138.
8. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000, 6:1375-1379.
9. Crotty S., Cameron C., Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis?. J. Mol. Med. 2002, 80:86-95.
10. Dou, J., Chen, L., Xu, G., Zhang, L., Zhou, H., Wang, H., Su, Z., Ke, M., Guo, Q., Zhou, C., 2011. Effects of baicalein on Sendai virus in vivo are linked to serum baicalin and its inhibition of hemagglutinin-neuraminidase. Arch. Virol. doi: doi:10.1007/s00705-011-0917-z.
11. Eggleston M. Clinical review of ribavirin. Infect. Control 1987, 8:215-218.
12. Eshaghi A., Bolotin S., Burton L., Low D.E., Mazzulli T., Drews S.J. Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season. J. Clin. Virol. 2009, 45:142-145.
13. Evers D.L., Chao C.F., Wang X., Zhang Z., Huong S.M., Huang E.S. Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action. Antiviral Res. 2005, 68:124-134.
14. Galabov A.S., Simeonova L., Gegova G.R. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir. Chem. Chemother. 2006, 17:251-258.
15. García-García J., Ramos C. Influenza, an existing public health problem. Salud Publica Mex. 2006, 48:244-267.
16. Higgins R.R., Eshaghi A., Burton L., Mazzulli T., Drews S.J. Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto. Canada. J. Clin. Virol. 2009, 44:91-93.
17. Hung H.C., Tseng C.P., Yang J.M., Ju Y.W., Tseng S.N., Chen Y.F., Chao Y.S., Hsieh H.P., Shih S.R., Hus J.T. Aurintricarboxylic acid inhibits influenza virus neuraminidase. Antiviral Res. 2009, 81:123-131.
18. Ilyushina N.A., Hoffmann E., Salomon R., Webster R.G., Govorkova E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 2007, 12:363-370.
19. Ilyushina N.A., Hay A., Yilmaz N., Boon A.C., Webster R.G., Govorkova E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52:3889-3897.
20. Kim Y., Narayanan S., Chang K.O. Inhibition of influenza virus replication by plant-derived isoquercetin. Antiviral Res. 2010, 88:227-235.
21. Kitamura K., Honda M., Yoshizaki H., Yamamoto S., Nakane H., Fukushima M., Ono K., Tokunaga T. Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res. 1998, 37:131-140.
22. Lamb R.A., Lai C.J., Choppin P.W. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proc. Natl. Acad. Sci. USA. 1981, 78:4170-4174.
23. Lyles D.S., McKenzie M., Parce J.W. Subunit interactions of vesicular stomatitis virus envelope glycoprotein stabilized by binding to viral matrix protein. J. Virol. 1992, 66:349-358.
24. Ma Z., Otsuyama K., Liu S., Abroun S., Ishikawa H., Tsuyama N., Obata M., Li F.J., Zheng X., Maki Y., Miyamoto K., Kawano M.M. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 2005, 105:3312-3318.
25. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560.
26. Nguyen J.T., Hoopes J.D., Smee D.F., Prichard M.N., Driebe E.M., Engelthaler D.M., Le M.H., Keim P.S., Spence R.P., Went G.T. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 2009, 53:4115-4126.
27. Nguyen J.T., Hoopes J.D., Le M.H., Smee D.F., Patick A.K., Faix D.J., Blair P.J., de Jong M.D., Prichard M.N., Went G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. Plos one 2010, 5:e9332.
28. Ono K., Nakane H., Fukushima M., Chermann J.C., Barré-Sinoussi F. Inhibition of reverse transcriptase activity by a flavonoid compound, 5,6,7-trihydroxyflavone. Biochem. Biophys. Res. Commun. 1989, 160:982-987.
29. Ono K., Nakane H., Fukushima M., Chermann J.C., Barré-Sinoussi F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur. J. Biochem. 1990, 190:469-476.
30. Parker B.W. Metabolism and antiviral activity of ribavirin. Virus Research 2005, 107:165-171.
31. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14:181-205.
32. Reece P.A. Neuraminidase inhibitor resistance in influenza viruses. J. Med. Virol. 2007, 79:1577-1586.
33. Saito R., Li D., Suzuki Y., Sato I., Masaki H., Nishimura H., Kawashima T., Shirahige Y., Shimomura C., Asoh N., Degawa S., Ishikawa H., Sato M., Shobugawa Y., Suzuki H. High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season. J. Med. Virol. 2007, 79:1569-1576.
34. Smee D.F., Bailey K.W., Morrison A.C., Sidwell R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002, 48:88-93.
35. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Morrey J.D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 2009, 53:2120-2128.
36. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Tarbet E.B., Morrey J.D., Furuta Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infection in mice. Antimicrob. Agents Chemother. 2010, 54:126-133.
37. Smee D.F., Hurst B.L., Wong M.H., Tarbet E.B., Babu Y.S., Klumpp K., Morrey J.D. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010, 88:38-44.
38. Streeter D.G., Witkowski J.T., Khare G.P., Sidwell R.W., Bauer R.J., Robins R.K., Simon L.N. Mechanism of action of 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 1973, 70:1174-1178.
39. Tam R.C., Ramasamy K., Bard J., Pai B., Lim C., Averett D.R. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob. Agents Chemother. 2000, 44:1276-1283.
40. Triana-Baltzer G.B., Gubareva L.V., Klimov A.I., Wurtman D.F., Moss R.B., Hedlund M., Larson J.L., Belshe R.B., Fang F. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. Plos one 2009, 4:e7838.
41. van der Sluijs K.F., van Elden L.J., Nijhuis M., Schuurman R., Pater J.M., Florquin S., Goldman M., Jansen H.M., Lutter R., van der Poll T. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J. Immunol. 2004, 172:7603-7609.
42. Vignuzzi1 M., Stone1 J.K., Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 2005, 107:173-181.
43. Wang L., Ling Y., Chen Y., Li C.L., Feng F., You Q.D., Lu N., Guo Q.L. Flavonoid baicalein suppresses adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. Cancer Lett. 2010, 297:42-48.
44. Xu G., Dou J., Zhang L., Guo Q., Zhou C. Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum. Biol. Pharm. Bull. 2010, 33:238-243.
45. Yang D., Hu H., Huang S., Chaumont J.P., Millet J. Study on the inhibitory activity, in vitro, of baicalein and baicalin against skin fungi and bacteria. Zhong Yao Cai 2000, 23:272-274.
46. Yang J.H., Yun M.Y., Lee N.H., Kim D.K., Kim Y.I., Noh Y.H., Kim T.Y., Yoon S.W., Shin S.C. The effects of ketorolac tromethamine and baicalein on the levels of inflammatory factors in human synoviocytes. Arch. Pharm. Res. 2008, 31:1517-1523.